| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97bd68cb0a98913a5940c708e7ce1679
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_adf225ca4a6bf6190b6a2763410d1ebf |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5123
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate |
2017-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_514e22b229340d4040bc746ecf6b0d68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f9d3e1d6a0551ba2eb788073d8b33dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4da8e548397b4ab134cae220c4f22ccc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c09ce5118babc9ccf6a634e1d7760bf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f9b4cfee65d5be92591abcdc2420c04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4971e4046abf0435f5bd5ab9ff6fb58d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09efbcfd17ee81338e69f151ae6eca29 |
| publicationDate |
2019-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3445334-A1 |
| titleOfInvention |
Nanoliposomes for sustained delivery of tacrolimus for treatment of anterior segment eye diseases |
| abstract |
According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes. |
| priorityDate |
2016-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |